Deeper insights. Better outcomes.

The IDEXX inVue Dx[™] Cellular Analyzer leverages the power of the ProCyte One[®] and ProCyte Dx[®] hematology analyzers by automatically integrating the RBC, HCT, and WBC values, informing the morphological assessment.

+

Quantification of changes in red blood cell morphology and immature neutrophils enable trending over time.

Platelets are quantified even in the presence of clumping.

Composite image gallery supports the Al-assisted pathology results.

Diagnostic Considerations guide real-time clinical decisions.



© 2024 IDEXX Laboratories, Inc. All rights reserved. • 09-2691234-00 All @/TM marks are owned by IDEXX Laboratories, Inc. or its affiliates in the United States and/or other countries. The IDEXX Privacy Policy is available at idexx.com.

- 1	DE	XX VetConnect	PLUS Home	Directory of Services	Imaging 1	Felemedicine	2			
ZOE CLARK 203AB Patient Management ~ Canine Brussels Griffon Female 8y 2024 Jan 27 Jan 27										
Result Details Y Add to Order										0
			1/27/24						1/27/24	
	He	ematology	1/27/24 9:43 AM						9:43 AM	i
AR.	~	RBC	a. 1.09	5.65 - 8.87 M/µL	٩				1.09	
RR	~	Hematorcrit	b. <mark>9.8</mark>	37.3 - 61.7 %	۲				9.8	
AA.		Spherocytes	60% (Marked))						
RR		Agglutination	Present							
AA		% Reticulocyte	17.0	96					17.0	
RA	~	Reticulocytes	184.8	10.0 - 110.0 K/µL					184.8	
RR	~	WBC	c. 43.20	5.05 - 16.76 K/µL					43.20	
AA		% Neutrophils	69.5	%					*69.2	
AR		% Immature Neutrophils	18.5	96						
AA		% Lymphocytes	1.9	96					*21.6	
AA		% Monocytes	9.7	96					*8.9	
AA		% Eosinophils	0.2	96					0.2	
AA		% Basophils	0.1	%					0.1	
AA.	~	Neutrophils	30.02	2.95 - 11.64 K/µL					*29.89	
RR		Immature Neutrophils	7.99	K/pL						
AR.	~	Lymphocytes	0.84	1.05 - 5.10 K/µL		1			*9.34	
RR	~	Monocytes	4.20	0.16 - 1.12 K/µL					*3.85	
AR.	~	Eosinophils	0.09	0.06 - 1.23 K/µL		1			0.09	
RR	~	Basophils	0.03	0.00 - 0.10 K/µL		1			0.03	
88		Platelet Estimate	50-100 K/μL (Μ	Moderately decreased)						
		Diagnostic Considerations	The presence of regenerative anemia, spherocytosis, and RBC agglutination are strongly suggestive of immune-mediated hemolytic anemia. Other clinical features include icterus, hyperbilirubinemia/bilirubinuria (in the absence of liver dysfunction), or hemoglobinemia/uria. Investigate for underlying causes such as infection, neoplasia, concurrent inflammatory conditions, or history of recent drugs/vaccines. This platelet estimate incorporates enumeration of individual platelets and platelets within clumps. Moderately decreased platelets may be seen with platelet consumption, immune-mediated destruction, decreased production from the bone marrow, and sequestration in the spleen. If this finding is unexpected, please redraw a new sample to rule out artifactual							

thrombocytopenia (e.g., clot in the blood tube).

Images

